Promoting best gynecologic oncology practice: a role for the Society of Gynecologic Oncologists of Canada by Elit, L.M. et al.
94
CURRENT ONCOLOGY—VOLUME 13, NUMBER 3
ELIT et al.
ABSTRACT
During March 30–April 1, 2005, the Society of Gy-
necologic Oncologists of Canada (GOC) and the Ca-
nadian Strategy for Cancer Control (CSCC) Clinical
Practice Guidelines Action Group (CPG-AG) met to
• determine how GOC would like to influence prac-
tice in the care of women with gynecologic cancer.
• explore a collaborative model for developing and
implementing evidence-based practice guidelines.
• investigate the utility of the CPG evaluation and
adaptation cycle as a tool for selecting, adapting,
and adopting guidelines.
At the workshop meeting, 21 members of the GOC
and the CPG-AG heard presentations from various Ca-
nadian guideline initiatives. As an example of adap-
tation and adoption processes, the AGREE (Appraisal
of Guidelines for Research and Evaluation) tool was
applied to guidelines in recurrent ovarian cancer, and
the group explored their opportunity to use knowl-
edge translation to influence the care of women with
gynecologic cancer.
The themes influencing practice are consistent
with  GOC’s mandate. The future is expected to involve
partnering with other groups to maximize scarce re-
sources. Resources should be directed to facilitating
implementation of existing guidelines rather than to
developing new documents. The full spectrum of
cancer care includes prevention, screening, diagno-
sis, primary treatment, follow-up, treatment of recur-
rent disease, and palliation. High-quality evidence is
available in some areas, but gaps exist where guide-
line panels could provide guidance. Development of
a pan-Canadian gynecologic oncology process could
provide an opportunity to influence access to care at
the political and policy levels.
The GOC will develop linkages such that the
toolbox available through CSCC-CPG-AG can be incor-
porated into future collaboration.
KEY WORDS
Practice guidelines, gynecologic oncology
1. INTRODUCTION
Members of the Society of Gynecologic Oncologists
of Canada (GOC) and the Canadian Strategy for Can-
cer Control (CSCC) Clinical Practice Guidelines Ac-
tion Group (CPG-AG) came together (Table I) in March
2005 in a workshop setting. The GOC is an associa-
tion of physicians specializing in gynecologic can-
cer care, whose purpose is “to improve the care of
women with gynaecologic cancer, to raise standards
of practice in gynecologic oncology and to encour-
age ongoing research” 1. The CPG-AG has a mandate
to champion, through national collaboration, a pan-
Canadian strategy to facilitate the optimal use of evi-
dence for cancer control 2. A partnership between
these two groups has the potential to address the gap
between knowledge and practice in the care of women
with gynecologic cancer and to reduce variation in
access to best clinical care across Canada.
Clinical practice guidelines (defined as system-
atically developed statements meant to assist health
care decisions in specific clinical circumstances) are
a common mechanism for transferring evidence from
clinical research into practice and for influencing cli-
nician behaviour. Several provinces develop practice
guidelines, and additional guidelines are available
from other groups within and outside of Canada.
Unfortunately, existing guidelines that address a given
clinical situation may vary with regard to the
methodologic quality of their development and to the
recommendations made. These inconsistencies can
cause confusion for clinicians and patients. Additional
challenges can arise from suboptimal dissemination
and implementation strategies. Guidelines are meant
to enhance care, and the barriers that hamper the trans-
lation of new knowledge and guideline recommen-
dations into clinical practice can also hinder effective
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uptake of other types of systematic clinical advice,
such as targeted messaging and clinical leadership.
Not all institutions, provinces, and professional
associations have the resources necessary to develop,
disseminate, implement, and evaluate guidelines. And
in any case, reviewing a common evidence base and
developing parallel guidelines represents a duplica-
tion of effort that does not make sense in the face of
numerous competing demands on scarce resources.
Where high-quality guidelines exist, adoption—with
or without adaptation of the recommendations to re-
flect local circumstances and values—may be pref-
erable to developing new guidelines. Canada has
people with acknowledged expertise in both guide-
line development and guideline adaptation; many of
those experts participated in the workshop.
Groups such as GOC not only can add credibility
to guidelines by endorsing them, but they can also
provide vital networks for guideline dissemination,
implementation, and evaluation. As education
influentials in the gynecologic oncology community,
GOC members can also make a unique contribution to
interpretation of evidence, provision of clinical con-
text, identification of gaps in the evidence, and pro-
vision of well-reasoned expert opinion to fill the gaps
until further research is completed.
With those issues in mind, the workshop agenda
focused on three sets of objectives:
• To determine if GOC wants to actively influence
practice in the care of women with gynecologic
cancer, and if so, the methods to be used. Spe-
cifically, to determine if GOC should take an ac-
tive leadership role in guideline development,
adaptation, implementation, or evaluation, and to
determine the extent to which such activities are
to be evidence-based.
• To explore a collaborative model for designing a
pan-Canadian strategy to develop and implement
evidence-based clinical practice guidelines for
gynecologic oncology.
• To investigate the utility of an established meth-
odology, the CPG Evaluation and Adaptation
Cycle 3, as a tool for selecting, adapting, and adopt-
ing guidelines for gynecologic oncology—start-
ing with a pilot test of the Adaptation Cycle
focusing on the management of recurrent ovarian
cancer. The Cycle would be used to generate spe-
cific recommendations for the Canadian context.
The present report describes discussions related to
the first two sets of objectives. Methods, results, and
conclusions associated with the CPG Evaluation and
Adaptation Cycle will be described in a separate
report.
2. MATERIALS AND METHODS
As a preliminary step for all workshop activities,
participants were provided with common background
information through a review of three different pro-
vincial approaches (those of British Columbia, On-
tario, and Quebec) for developing practice guidelines
and treatment policies, a summary of the experience
of the Society of Obstetricians and Gynecologists of
Canada (SOGC) with national guidelines, and an over-
view of CPG adaptation and adoption models and
methods 3–5. A specific example of a contentious clini-
cal problem—treatment of recurrent ovarian cancer—
was explored through a review of the current clinical
issues, appraisal by workshop participants of three
available guidelines (from the Cancer Care Ontario
Program in Evidence-based Care 6, the Scottish In-
ternational Guidelines Network 7,8, and the British
Columbia Cancer Agency 9), and a comparison of the
recommendations made in the three guidelines plus
supporting information in the form of two other ad-
vice documents (from the National Cancer Institute
Physician Data Query Web site 10 and the National
Institute for Health and Clinical Excellence 11,12).
Following those activities, breakout groups (each
consisting of six people) addressed all three key ques-
tions related to GOC’s role in influencing practice:
• Does GOC want to influence practice in women
with gynecologic cancer?
• What methods should GOC use to inform practice
at a pan-Canadian level?
• What role should an evidence-based process play
in influencing practice?
TABLE I Workshop participants
Members of the Society of Gynecologic Oncologists of Canada
(GOC)
Peter Craighead, Alberta
Lesa Dawson, Newfoundland
Laurie Elit, Ontario
Michael Fung Kee Fung, Ontario
Prafull Ghatage, Alberta
Walter Gotlieb, Quebec
Robert Lotocki, Manitoba
Dianne Miller, British Columbia
Joan Murphy, Ontario
Diane Provencher, Quebec (GOC President)
Barry Rosen, Ontario
Rejean Savoie, New Brunswick
Luis Souhami, Quebec
Gavin Stuart, British Columbia
Ken Swenerton, British Columbia
Members of the Canadian Strategy for Cancer Control Clinical
Practice Guidelines Action Group (CSCC-CPG-AG)
Melissa Brouwers, Ontario
George Browman, Alberta (CSCC-CPG-AG Chair)
Ian Graham, Ontario
Louise Paquet, Quebec
Jill Petrella, Nova Scotia
Coordinator of the Clinical Practice Guidelines Adaptation
Project
Louise Zitzelsberger96
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Following small-group discussion of each ques-
tion, the individual groups reported their thoughts for
further discussion by all participants before moving
to the next question.
3. RESULTS
Issues emerging from discussion during the breakout
and plenary sessions related to four key themes:
• The current and future role of GOC
• Making the most of limited resources
• Providing guidance across the full continuum
of care
• Influencing funding for cancer care with a view
to facilitating equity of access across provinces
Workshop participants agreed that influencing
practice is consistent with GOC’s mandate and is sup-
ported by its mission statement. Moreover, GOC may
be the group most likely to effectively influence prac-
tice across Canada. Currently, GOC is viewed as hav-
ing an advisory and educational role. The group could
build on that experience by developing a more “out-
ward looking” approach that would move their in-
fluence beyond GOC’s membership to other specialty
groups and trainees and that would solidify GOC’s role
as a knowledge broker for other clinicians. This pro-
cess could start by dealing with the large unfilled
demand from gynecologists outside cancer centres
for leadership and high-quality, implementable guide-
lines related to cancer care.
Some debate occurred about the range of guide-
line topics that GOC should consider, leading to the
conclusion that oncology topics (such as systemic
therapy for ovarian cancer) should be tackled first.
Strengths on which GOC can draw include its inter-
disciplinary approach and its experience with con-
tinuing medical education over the Internet.
In addition to aiding in clinical decision-making,
practice guidelines can have educational value. Plans
to endorse information for patients with gynecologic
cancer could also be incorporated into a program for
influencing practice. In mapping out future activi-
ties,  GOC should consider developing partnerships with
other groups to maximize scarce resources and to
explore funding opportunities. One of these partners
might be the SOGC, but the relationship between GOC
and the SOGC with respect to guideline development
and dissemination would need to be clearly defined.
For example, GOC guidelines would likely be devel-
oped independently of SOGC, but SOGC members could
provide feedback on draft guidelines, and the SOGC
may wish to endorse GOC guidelines for use by gyne-
cologists across Canada.
The number of oncologists across Canada is lim-
ited. To address the need for additional resources,
the health care system should engage and educate a
broad range of practitioners (obstetrician–gynecolo-
gists, family physicians, etc.) to provide some aspects
of care to women with gynecologic cancers.
The human resource issues for providing care are
also reflected in the limited number of individuals
available to develop guidelines and other mechanisms
to influence practice. In many cases, the same clini-
cians who deliver care to patients and act as practice
leaders would be the key players in guideline devel-
opment. In light of limited infrastructure and re-
sources for influencing practice, workshop
participants wondered if such resources should be
directed to facilitating implementation of existing
guidance rather than to developing new guidance
documents. Broad participation in guideline- and
policy-development activities may require a cultural
shift for some practice communities so that time is
allocated for this work. Such a shift may be more
challenging in some settings (the surgical commu-
nity, for example) than in others. However, success-
ful involvement of clinicians across Canada in
guideline development, endorsement, dissemination,
and implementation has the potential to build capac-
ity, reduce duplication of effort, and improve patient
care and outcomes. Evaluating the impact of these
new activities on practice and patient outcomes will
be critical.
The full spectrum of cancer care includes pre-
vention, screening, diagnosis, primary treatment (sur-
gery, radiotherapy, chemotherapy), follow-up,
treatment of recurrent disease, and palliation. The
availability of high-quality evidence varies across this
continuum, as does the need for guidance to clini-
cians and patients. In some cases, guidance is needed
in circumstances where evidence of effectiveness is
absent, inconsistent, or unclear. The result can be
clinical uncertainty and variation in practice. Evi-
dence-based guidelines help to inform clinical deci-
sions by making recommendations based on a
systematic review and interpretation of the available
evidence. Where gaps in the evidence exist, guide-
line panels could provide guidance by using a for-
malized process to make recommendations based on
expert opinion.
Activities other than practice guidelines that may
influence care include continuous professional de-
velopment (CPD), patient advocacy, lobbying, treat-
ment policies, algorithms, care paths, consensus
statements, patient information, and clinical research.
Many of these activities can be informed by evidence-
based practice guidelines.
Developing a pan-Canadian perspective on key
issues in gynecologic oncology could provide the
opportunity to influence funding and access to care
at the political and policy level. It could also allow
clinicians to organize themselves as advisors and
knowledge brokers to funding agencies. To effectively
engage in such activities—and in others suggested at
the workshop—collaboration across provincial
boundaries would be necessary.CURRENT ONCOLOGY—VOLUME 13, NUMBER 3
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4. DISCUSSION
The GOC wants to use partnerships with other groups
such as the SOGC, the Canadian Association of Radia-
tion Oncologists, the Canadian Association of Medi-
cal Oncologists, the National Ovarian Cancer
Association, provincial specialty groups, guideline
developers in the provinces, and the CSCC-CPG-AG to
influence practice in women with gynecologic can-
cer. The methods that GOC should use to inform prac-
tice include identifying unmet needs for clinical advice
in managing gynecologic cancers—for example, de-
fining and developing a broad but relevant audience,
and exploring opportunities to build accountability
among clinicians for participating in guideline-related
activities. The Society can build on work already being
done for CPD. The GOC Web site, with access through
the SOGC Web site, could be developed as a communi-
cation tool for these and future activities.
For the time being, efforts should concentrate on
guideline implementation issues, because develop-
ing practice guidelines requires infrastructure and
resources not currently available to GOC. However,
adoption or adaptation of guidelines developed by
others may be possible. At the workshop, GOC mem-
bers expressed interest in participating in research
on the further development of guideline adaptation
processes. They also suggested using GOC opinion
leaders to build consensus among practitioners. The
evidence-based process (including guideline adapta-
tion) was endorsed as an approach to providing ad-
vice to clinicians.
The Society is in an ideal position to identify
common issues in practice as priorities for guidance
documents across the entire spectrum of care in gy-
necologic oncology, from prevention through to pal-
liation. The Society’s role is to promote a culture of
evidence-based practice in gynecologic oncology. As
clinical experts, GOC members could also respond to
emerging evidence.
In addition to endorsing or adapting evidence-
based guidelines from other groups, GOC could con-
sider partnering with groups that develop
evidence-based guidelines to work on new guidelines
or to update existing guidelines. Such work should
be based on a defined process or structure, with in-
volvement of appropriate experts in guideline and
clinical research methods. Criteria—for example,
need, potential impact on care, quality of the evidence
base, availability of an existing systematic review or
guideline—should be defined for choosing topics for
guideline development or adaptation. Guidelines and
other advice documents should include the patient
perspective and an economic evaluation. When avail-
able, existing systematic reviews and good-quality
guidelines could be the starting point for an evidence-
based approach. Where evidence is insufficient, a for-
malized consensus process could be used to develop
advice.
The Society could also contribute by identifying
gaps in the evidence and advocating for appropriate
clinical trials to fill those gaps. With its partners, GOC
should develop explicit implementation and evalua-
tion strategies based on evidence of effectiveness.
5. CONCLUSION
Overall, participants concurred that the workshop was
a positive experience. Based on the presentations and
ensuing discussion, they concluded that effective tools
exist for guideline development, adaptation, and
adoption, but that delivering guidelines to practitio-
ners during the patient encounter presents a signifi-
cant challenge. It became clear during the workshop
that GOC and CPG-AG have common objectives with
respect to influencing clinical practice.
When the workshop took place, the AG was still
determining its mandate, the scope of its activities,
and a model for a pan-Canadian approach. Repre-
sentatives of the AG found the workshop to be useful
as a pilot test for developing beneficial partnerships
in the future. The GOC representatives concluded that
GOC has a mandate to use clinical education to influ-
ence care and that this mandate may extend to other
activities such as providing evidence-based advice
to practitioners.
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